Pharmaceuticals Acquisitions in Minnesota

Bora Pharmaceuticals completed a 2024 acquisition of Upsher-Smith Laboratories for $210 million and is expanding the Maple Grove, Minnesota manufacturing site with a multi-year buildout. The investment includes installation of a Gerteis Macro-Pactor (operational Q3 2025) and development of 100,000 square feet of shell space to boost oral solid dose (OSD) contract development and manufacturing capabilities.

U.S. Pharmacopeia (USP) has acquired Stratix Labs, a Saint Paul, Minnesota-based microbiology technology company, to expand USP’s microbiological quality-control offerings and contamination-control capabilities. The acquisition brings Stratix Labs' microbial preservation products and the Enverify competency solution into USP’s portfolio to better serve pharmaceutical manufacturers, biopharma developers, and compounding entities.

LTS LOHMANN Therapie-Systeme AG (LTS) has completed the acquisition of Tapemark Inc., a U.S.-based CDMO specializing in transdermal drug delivery systems and oral thin films. The deal integrates Tapemark’s St. Paul (West St. Paul), Minnesota facility into LTS’s global network to strengthen LTS’s U.S. footprint, expand manufacturing capacity and R&D capabilities, and broaden its drug-delivery technology portfolio.